2024 JP Morgan Healthcare Conference
■
■
■
BRUKER AN EMERGING LEADER OF THE POST-GENOMIC ERA
■
Dual strategy of Project Accelerate 2.0 and Operational Excellence works
Project Accelerate 2.0 Initiatives
Pull up growth and EPS
Re-positioning Bruker for high-growth,
high-margin opportunities
Building unique, leading platforms for
novel applications, life-science solutions
Enabling research in cell and disease
biology: large TAMS, strong secular growth
Project Accelerate 2.0 at ~56% of revenue,
with DD revenue CAGR
→ Major benefits from Al and Clean-Tech
Assays, Software
& Aftermarket
2023 Bruker
Next-gen Nano
& Semi Tools
Unbiased
Proteomics &
Multiomics
BRUKER
Biopharma &
Applied
Microbiology &
Molecular Dx
Spatial Biology,
Single-Cell Omics,
Cellular Analysis
Operational Excellence
▪ Push up market share, gross margin
▪ Bruker Management Process drives
execution and predictability
■
■
BRUKER
Operational, commercial and
product R&D excellence
Disciplined execution: significant
investments and organic margin
expansion, non-GAAP EPS growth,
all at high ROIC
→ Emerging Leadership of the Post-Genomic Era
Prudent capital allocation with
conservative margin of safety
Innovation with Integrity |
January 8, 2024
I
24View entire presentation